Mutational activation of the K-ras oncogene and the effect of chemotherapy in advanced adenocarcinoma of the lung: a prospective study.

PURPOSE To determine whether the clinical course and the response to chemotherapy of patients with advanced adenocarcinoma of the lung depends on the presence or absence of a ras mutation in the tumor. Mutational activation of K-ras is a strong adverse prognostic factor in stage I or II lung cancer and laboratory studies have suggested that ras mutations lead to resistance against ionizing radiation and chemotherapy. PATIENTS AND METHODS Patients with advanced adenocarcinoma of the lung with measurable or assessable disease received chemotherapy with mesna, ifosfamide, carboplatin, and etoposide (MICE). Archival biopsies, fresh biopsies, or fine-needle aspirations were tested for the presence of ras gene mutations. Associations of ras mutations with clinical characteristics, response to chemotherapy, and survival were studied. RESULTS The presence or absence of ras gene mutations could be established in 69 of 83 patients (83%). A total of 261 courses of MICE were administered to 62 informative patients, 16 of whom were shown to have a K-ras mutation-positive tumor. The frequency of mutations (26%) and the type of mutations closely matched the pattern we have previously reported in operable disease. Patients with a ras mutation in their tumor were more likely to have a close relative with lung cancer, but other clinical characteristics, such as pattern of metastases, response, and survival, were similar between the ras mutation-positive and ras mutation-negative groups. CONCLUSION Patients with advanced lung adenocarcinoma who harbor a ras mutation may have major responses to chemotherapy and have similar progression-free and overall survival as patients with ras mutation-negative tumors. K-ras mutations may represent one of several ways in which early tumors are enabled to metastasize to distant sites.

[1]  S. Rodenhuis,et al.  K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. , 1990, The New England journal of medicine.

[2]  S. Rodenhuis,et al.  Mutational activation of the K-ras oncogene. A possible pathogenetic factor in adenocarcinoma of the lung. , 1987, The New England journal of medicine.

[3]  J. Mate,et al.  Prognostic impact of mutated K-ras gene in surgically resected non-small cell lung cancer patients. , 1993, Oncogene.

[4]  John G. Collard,et al.  Invasive and metastatic potential induced by ras-transfection into mouse BW5147 T-lymphoma cells. , 1987, Cancer research.

[5]  L. Liotta,et al.  Harvey ras induction of metastatic potential depends upon oncogene activation and the type of recipient cell. , 1985, The American journal of pathology.

[6]  S. Steinberg,et al.  ras gene mutations in non-small cell lung cancers are associated with shortened survival irrespective of treatment intent. , 1991, Cancer research.

[7]  M. Sklar.  The ras oncogenes increase the intrinsic resistance of NIH 3T3 cells to ionizing radiation. , 1988, Science.

[8]  J. Marx.  New genes may shed light on cell growth control. , 1992, Science.

[9]  J. Wanders,et al.  Dose-finding studies with carboplatin, ifosfamide, etoposide, and mesna in non-small cell lung cancer. , 1990, Seminars in oncology.

[10]  I. Weinstein,et al.  Rapid and sensitive nonradioactive detection of mutant K-ras genes via 'enriched' PCR amplification. , 1991, Oncogene.

[11]  K. Sugimachi,et al.  ras gene mutations as a prognostic marker in adenocarcinoma of the human lung without lymph node metastasis. , 1992, Cancer research.

[12]  A. Gazdar,et al.  Correlation of intrinsic chemoresistance of non-small-cell lung cancer cell lines with HER-2/neu gene expression but not with ras gene mutations. , 1993, Journal of the National Cancer Institute.

[13]  I. Pastan,et al.  Modulation of activity of the promoter of the human MDR1 gene by Ras and p53. , 1992, Science.

[14]  S. Rodenhuis,et al.  K‐ras oncogene activation in lung adenocarcinomas from former smokers evidence that K‐ras mutations are an early and irreversible event in the development of adenocarcinoma of the lung , 1993 .

[15]  R. Weinberg.  ras Oncogenes and the molecular mechanisms of carcinogenesis. , 1984, Blood.

[16]  S. Rodenhuis,et al.  A Rapid and Simple Procedure for the Routine Detection of ras Point Mutations in Formalin‐Fixed, Paraffin‐Embedded Tissues , 1992, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[17]  D. Kerr,et al.  H-ras infection in mink lung epithelial cells may induce "atypical" multidrug resistance. , 1991, European journal of cancer.

[18]  L. Liotta,et al.  NIH/3T3 cells transfected with human tumor DNA containing activated ras oncogenes express the metastatic phenotype in nude mice , 1985, Molecular and cellular biology.

[19]  D. Samid,et al.  Increased radiation resistance in transformed and nontransformed cells with elevated ras proto-oncogene expression. , 1991, Radiation research.

[20]  C. Ling,et al.  Synergistic effect of the v-myc oncogene with H-ras on radioresistance. , 1990, Cancer research.

[21]  Yusuke Nakamura,et al.  Detection of K‐ras mutation in sputum by mutant‐allele‐specific amplification (MASA) , 1993, Human mutation.

[22]  D. Shibata,et al.  c-k-ras and p53 mutations occur very early in adenocarcinoma of the lung. , 1994, The American journal of pathology.

[23]  C. Ling,et al.  The role of the H-ras oncogene in radiation resistance and metastasis. , 1990, International journal of radiation oncology, biology, physics.

[24]  S. Rodenhuis,et al.  Incidence and possible clinical significance of K-ras oncogene activation in adenocarcinoma of the human lung. , 1988, Cancer research.

[25]  S. Rodenhuis,et al.  Relationship between K-ras oncogene activation and smoking in adenocarcinoma of the human lung. , 1991, Journal of the National Cancer Institute.

[26]  J. Bos,et al.  A dot-blot screening procedure for mutated ras oncogenes using synthetic oligodeoxynucleotides. , 1986, Gene.